New Immunotherapies and Targeted Therapies to Treat Lymphoma

January 9, 2018
Greg Guthrie, ASCO staff

The 2017 American Society of Hematology (ASH) Annual Meeting was held last month in Atlanta, Georgia. This meeting brings together experts from across the globe so they can discuss new advances in the treatment of different types of blood-related diseasesshare on twitter including a group of cancers called lymphoma.

In this podcast, Michael E. Williams, MD, ScM, highlights some of the research presented at the meeting that may improve the treatment of lymphoma.

  • A study examined whether adding brentuximab vedotin (Adcetris), a targeted therapy, to a chemotherapy combination used to treat Hodgkin lymphoma can keep the disease in remission longer than the current standard of care [1:59].

  • New targeted therapies are being studied to treat mantle cell lymphoma and other B-cell non-Hodgkin lymphomas [4:22].

  • Two studies looked at using chimeric antigen receptor (CAR) T-cell therapy to treat lymphoma that has returned following treatment [7:02].

Dr. Williams is the Lineagotica Associate Editor for lymphoma.

This is a prerecorded audio podcast. It can be listened to online or downloaded to your computer. A transcript of this podcast is also available. For more information, visit the Lineagotica podcast page.